SCHEMBL294330

SCHEMBL294330

C1=CC2=C3CNCCC3NC2C=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6933560 0.85
SCHEMBL29114759 0.76
SCHEMBL34467252 0.72
SCHEMBL4791875 0.67
SCHEMBL9687572 0.67
SCHEMBL611093 0.67
SCHEMBL6668165 0.66
SCHEMBL6757994 0.65
SCHEMBL8002495 0.65
SCHEMBL17318048 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010014758-A1 USE OF HYDROGENATED PYRIDO[4,3-B] INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS EDISON PHARMACEUTICALS, INC. (US) 2010-02-04 WO claimed
EP-1414819-B1 THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES PHARMACIA & UPJOHN CO LLC (US) 2005-10-12 EP claimed
EP-1414819-A1 THERAPEUTIC 1H-PYRIDO 4,3-b]INDOLES PHARMACIA &amp; UPJOHN COMPANY (US) 2004-05-06 EP claimed
WO-2003014118-A1 THERAPEUTIC 1H-PYRIDO[4,3-b]INDOLES PHARMACIA & UPJOHN COMPANY (US) 2003-02-20 WO claimed
EP-0876818-B1 AGENT FOR TREATING NEURO-DEGENERATIVE DISORDERS SELENA PHARMACEUTICALS INC (US) 2002-12-18 EP claimed
JP-52036697-A None JP disclosed
JP-52036696-A None JP disclosed
JP-55154972-A None JP disclosed
US-20250101022-A1 PROCESS FOR PREPARING INTERMEDIATES FOR 1-(4-FLUOROPHENYL)-4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3’,4’:4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)BUTAN-1-ONE INTRA-CELLULAR THERAPIES, INC. (US) 2025-03-27 US disclosed
US-12139490-B2 Process for preparing 1-(4-fluorophenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one INTRA-CELLULAR THERAPIES, INC. (US) 2024-11-12 US disclosed
US-20230404960-A1 DISORDERS IMPLICATING PUFA OXIDATION BIOJIVA LLC (US) 2023-12-21 US disclosed
US-20220332716-A1 SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS INTRA-CELLULAR THERAPIES, INC. (US) 2022-10-20 US disclosed
EP-0876818-B1 AGENT FOR TREATING NEURO-DEGENERATIVE DISORDERS SELENA PHARMACEUTICALS INC (US) 2002-12-18 EP disclosed
US-20020115682-A1 Agents for treating neurodegenerative disorders GRIGOR'EVA, I. V. (RU) 2002-08-22 US disclosed
US-20010020028-A1 Agents for treating neurodegenerative disorders YUROVSKAYA, M. A. (RU) 2001-09-06 US disclosed
US-6187785-B1 ADMINISTERING HYDROGENATED PYRIDO(4,3-B)INDOLE DERIVATIVES SUCH AS DIMEBOLIN TO TREAT ALZHEIMER*S DISEASE SELENA PHARMACEUTICALS, INC. 2001-02-13 US disclosed
EP-0876818-A2 AGENT FOR TREATING NEURO-DEGENERATIVE DISORDERS Zefirov, Nikolai Serafimovich (RU) 1998-11-11 EP disclosed
JP-S55154972-A HEXAHYDRO-1H-PYRIDO 4,3-B INDOLE DERIVATIVE DAINIPPON PHARMACEUT CO LTD 1980-12-02 JP disclosed
JP-S5236697-A PROCESS FOR PREPARATION OF HEXAHYDRO-1H- PYRIDO(4,3-B)-INDOLE DERIVATI VES DAINIPPON PHARMACEUT CO LTD 1977-03-22 JP disclosed
JP-S5236696-A PROCESS FOR PREPARATION OF HEXAHYDRO-1H- PYRIDO(4,3-B)-INDOLES DAINIPPON PHARMACEUT CO LTD 1977-03-22 JP disclosed